Skyhawk Therapeutics Announces Strategic Collaboration with Merck KGaA, Darmstadt, Germany to Discover Novel RNA-Targeting Small Molecules for Neurological Disorders

Skyhawk Therapeutics today announces a strategic research collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company.

Skyhawk Receives Australian Regulatory Approval to Extend SKY-0515 Treatment Duration in Phase 1 Huntington's Disease Patient Trial

Australian Human Research Ethics Committees approves SKY-0515 treatment for up to 12 weeks in the company's ongoing Phase 1 trial in patient

Skyhawk Therapeutics to Present Preclinical Data on SKY-1214 at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

SKY-1214, a first-in-class FANCL/FANCI RNA splicing modulator, demonstrated broad anti-cancer activity in multiple cancers, including...

Skyhawk Therapeutics Expands into State-of-the-Art Labs in its Basel, Switzerland Location

"Skyhawk has achieved tremendous scientific advances in our Basel Switzerland location so far," said Sergey Paushkin, CSO

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following...

Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small

SKY-0515 is a small molecule RNA splicing modifier developed through the company’s novel SKYSTAR®

Skyhawk Announces Collaboration Agreement with Sanofi for Oncology and Immunology Targets

Companies to leverage Skyhawk’s proprietary SkySTAR™ platform to discover and develop novel small molecules that modulate RNA splicing to...

Skyhawk Therapeutics Announces First Patient Dosed in Phase 2/3 FALCON-HD Trial of SKY-0515 for Huntington's Disease

Skyhawk presents today on its novel SKY-0515 small molecule RNA splicing modulator targeting Huntington's Disease

Skyhawk Therapeutics to Present Preclinical Data of SKY-1214 Combination Treatment in Hematologic Cancers at the 66th American Society of Hematology Annual Meeting

SKY-1214 demonstrates impressive synergistic anti-cancer activity in vivo and in vitro in combination with multiple commonly used and emergi

Skyhawk Therapeutics to Present Additional Positive Topline Data from Parts A and B of Phase 1 Clinical Trial of SKY-0515 at European Huntington's Disease Network and Enroll-HD 2024

The presentation highlights additional positive topline results from SAD/MAD study and preclinical data of SKY-0515, a novel small...

Skyhawk Therapeutics Promotes Clint Musil to Chief Executive Officer and Appoints Co-founder Bill Haney to Executive Chairman

Skyhawk today announced the promotion of Clint Musil, former Chief Financial Officer of Skyhawk Therapeutics, to Chief Executive Officer and

Ipsen dives into $1.8B Skyhawk pact to fire up RNA modulator R&D

Ipsen has swooped on a $1.8 billion R&D opportunity, joining with Skyhawk Therapeutics for the chance to option two candidates that could...

Drugging RNA

Small molecules that target messenger RNA have therapeutic potential, but the field still lacks an unqualified success.

Bill Haney’s latest startup scores deal from Sanofi its newest Big Pharma partner, with $54M upfront

A heavily financed biotech looking to drug RNA with small molecules is adding yet another company to its Big Pharma shortlist.

Skyhawk Therapeutics Presents at Huntington's Disease Youth Organization HDYO International Congress 2025

Skyhawk presents today on its novel SKY-0515 small molecule RNA splicing modulator targeting Huntington's Disease

Skyhawk Therapeutics Presents Compelling Preclinical Data on SKY-1214 at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

SKY-1214, an IND-ready first-in-class FANCL/FANCI RNA splicing modulator, demonstrates tumor growth inhibition and regression to undetectabl

Skyhawk Therapeutics Announces Positive Topline Results of SKY-0515 as a Treatment for Huntington’s Disease, Reaching 72% Huntingtin mRNA Reduction

Skyhawk’s SKY-0515 demonstrated dose-dependent huntingtin (HTT) mRNA reduction in healthy volunteers, with 72% reduction at the highest dose

Ipsen, Skyhawk ink deal worth up to $1.8B

Ipsen, Skyhawk Therapeutics pen neurological deal: Ipsen and Skyhawk plan to develop small molecules that can modulate RNA in a deal...

Skyhawk Has Advanced to Multiple Ascending Dose in it’s SKY-0515 Huntington’s Trial

SKY-0515 is a small molecule RNA splicing modifier developed through the company's novel SKYSTAR® platform.

Drugging RNA with Pills : Small Molecules for a Big Frontier

Can biotechnology startups turn what were once accidental discoveries into a purposeful way to hit hard-to-reach disease targets?